These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

317 related items for PubMed ID: 20530422

  • 1. Arsenic trioxide suppresses thymidylate synthase in 5-FU-resistant colorectal cancer cell line HT29 In Vitro re-sensitizing cells to 5-FU.
    Subbarayan PR, Lee K, Ardalan B.
    Anticancer Res; 2010 Apr; 30(4):1157-62. PubMed ID: 20530422
    [Abstract] [Full Text] [Related]

  • 2. Chronic exposure of colorectal cancer cells in culture to fluoropyrimidine analogs induces thymidylate synthase and suppresses p53. A molecular explanation for the mechanism of 5-FU resistance.
    Subbarayan PR, Sarkar M, Nelson G, Benitez E, Singhal S, Ardalan B.
    Anticancer Res; 2010 Apr; 30(4):1149-56. PubMed ID: 20530421
    [Abstract] [Full Text] [Related]

  • 3. Combined therapy with a thymidylate synthase-inhibiting vector and S-1 has effective antitumor activity against 5-FU-resistant tumors.
    Kadota K, Huang CL, Liu D, Yokomise H, Haba R, Wada H.
    Int J Oncol; 2011 Feb; 38(2):355-63. PubMed ID: 21174056
    [Abstract] [Full Text] [Related]

  • 4. A phase I study of 5-fluorouracil/leucovorin and arsenic trioxide for patients with refractory/relapsed colorectal carcinoma.
    Ardalan B, Subbarayan PR, Ramos Y, Gonzalez M, Fernandez A, Mezentsev D, Reis I, Duncan R, Podolsky L, Lee K, Lima M, Ganjei-Azar P.
    Clin Cancer Res; 2010 Jun 01; 16(11):3019-27. PubMed ID: 20501625
    [Abstract] [Full Text] [Related]

  • 5. CDK inhibitor enhances the sensitivity to 5-fluorouracil in colorectal cancer cells.
    Takagi K, Sowa Y, Cevik OM, Nakanishi R, Sakai T.
    Int J Oncol; 2008 May 01; 32(5):1105-10. PubMed ID: 18425338
    [Abstract] [Full Text] [Related]

  • 6. Dihydropyrimidine dehydrogenase but not thymidylate synthase expression is associated with resistance to 5-fluorouracil in colorectal cancer.
    Nita ME, Tominaga O, Nagawa H, Tsuruo T, Muto T.
    Hepatogastroenterology; 1998 May 01; 45(24):2117-22. PubMed ID: 9951876
    [Abstract] [Full Text] [Related]

  • 7. Expression level of thymidylate synthase mRNA reflects 5-fluorouracil sensitivity with low dose and long duration in primary colorectal cancer.
    Okumura K, Mekata E, Shiomi H, Naitoh H, Abe H, Endo Y, Kurumi Y, Tani T.
    Cancer Chemother Pharmacol; 2008 Apr 01; 61(4):587-94. PubMed ID: 17520254
    [Abstract] [Full Text] [Related]

  • 8. Enhanced 5-fluorouracil cytotoxicity in high cyclooxygenase-2 expressing colorectal cancer cells and xenografts induced by non-steroidal anti-inflammatory drugs via downregulation of dihydropyrimidine dehydrogenase.
    Réti A, Pap E, Adleff V, Jeney A, Kralovánszky J, Budai B.
    Cancer Chemother Pharmacol; 2010 Jul 01; 66(2):219-27. PubMed ID: 19830428
    [Abstract] [Full Text] [Related]

  • 9. Inhibition on LS-174T cell growth and activity of telomerase in vitro and in vivo by arsenic trioxide.
    Wang X, Wang G, Dong D, Fu S, Yang B.
    Exp Toxicol Pathol; 2008 Sep 01; 60(6):481-8. PubMed ID: 18606528
    [Abstract] [Full Text] [Related]

  • 10. Correlation between chemosensitivity and mRNA expression level of 5-fluorouracil-related metabolic enzymes during liver metastasis of colorectal cancer.
    Okumura K, Shiomi H, Mekata E, Kaizuka M, Endo Y, Kurumi Y, Tani T.
    Oncol Rep; 2006 Apr 01; 15(4):875-82. PubMed ID: 16525674
    [Abstract] [Full Text] [Related]

  • 11. The role of thymidylate synthase induction in modulating p53-regulated gene expression in response to 5-fluorouracil and antifolates.
    Longley DB, Boyer J, Allen WL, Latif T, Ferguson PR, Maxwell PJ, McDermott U, Lynch M, Harkin DP, Johnston PG.
    Cancer Res; 2002 May 01; 62(9):2644-9. PubMed ID: 11980662
    [Abstract] [Full Text] [Related]

  • 12. Arsenic trioxide induced the apoptosis of laryngeal cancer via down-regulation of survivin mRNA.
    Cheng B, Yang X, Han Z, An L, Liu S.
    Auris Nasus Larynx; 2008 Mar 01; 35(1):95-101. PubMed ID: 17869043
    [Abstract] [Full Text] [Related]

  • 13. Inhibition of Src tyrosine kinase reverts chemoresistance toward 5-fluorouracil in human pancreatic carcinoma cells: an involvement of epidermal growth factor receptor signaling.
    Ischenko I, Camaj P, Seeliger H, Kleespies A, Guba M, De Toni EN, Schwarz B, Graeb C, Eichhorn ME, Jauch KW, Bruns CJ.
    Oncogene; 2008 Dec 04; 27(57):7212-22. PubMed ID: 18794807
    [Abstract] [Full Text] [Related]

  • 14. The transfection of thymidylate synthase antisense suppresses oncogenic properties of a human colon cancer cell line and augments the antitumor effect of fluorouracil.
    Matsuoka K, Tsukuda K, Suda M, Kobayashi K, Ota T, Okita A, Watanabe K, Suzuki E, Murakami M, Doihara H, Shimizu N.
    Int J Oncol; 2004 Jan 04; 24(1):217-22. PubMed ID: 14654960
    [Abstract] [Full Text] [Related]

  • 15. A novel combination therapy with arsenic trioxide and parthenolide against pancreatic cancer cells.
    Wang W, Adachi M, Zhang R, Zhou J, Zhu D.
    Pancreas; 2009 May 04; 38(4):e114-23. PubMed ID: 19342982
    [Abstract] [Full Text] [Related]

  • 16. Influence of p53 status on radiation and 5-flourouracil synergy in pancreatic cancer cells.
    Mohiuddin M, Chendil D, Dey S, Alcock RA, Regine W, Mohiuddin M, Ahmed MM.
    Anticancer Res; 2002 May 04; 22(2A):825-30. PubMed ID: 12014658
    [Abstract] [Full Text] [Related]

  • 17. Enhancement of 5-fluorouracil sensitivity by an rTS signaling mimic in H630 colon cancer cells.
    Dolnick R, Wu Q, Angelino NJ, Stephanie LV, Chow KC, Sufrin JR, Dolnick BJ.
    Cancer Res; 2005 Jul 01; 65(13):5917-24. PubMed ID: 15994970
    [Abstract] [Full Text] [Related]

  • 18. Arsenic trioxide- and idarubicin-induced remissions in relapsed acute promyelocytic leukaemia: clinicopathological and molecular features of a pilot study.
    Kwong YL, Au WY, Chim CS, Pang A, Suen C, Liang R.
    Am J Hematol; 2001 Apr 01; 66(4):274-9. PubMed ID: 11279639
    [Abstract] [Full Text] [Related]

  • 19. Use of arsenic trioxide in haematological malignancies: insight into the clinical development of a novel agent.
    Amadori S, Fenaux P, Ludwig H, O'dwyer M, Sanz M.
    Curr Med Res Opin; 2005 Mar 01; 21(3):403-11. PubMed ID: 15811209
    [Abstract] [Full Text] [Related]

  • 20. Serine/threonine protein phosphatase inhibition enhances the effect of thymidylate synthase inhibition.
    Sakoff JA, Howitt IJ, Ackland SP, McCluskey A.
    Cancer Chemother Pharmacol; 2004 Mar 01; 53(3):225-32. PubMed ID: 14648018
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.